ThePeptideGuide.uk LogoNavigation

Educational purposes only. Not medical advice. Consult healthcare professionals before use.

Healing & Recovery
Preclinical

Tesofensine

Tesofensine

Also known as: NS2330, Tesomet

Overview

Key Facts

Primary Goal: Research and therapeutic applications of Tesofensine

Inhibits reuptake of norepinephrine, dopamine, and serotonin. Enhances sympathetic nervous system activity to boost thermogenesis.

Looking for the best price?

Compare live Tesofensine prices from 8+ verified UK & US suppliers

Compare Tesofensine prices →
Updated daily · Trusted suppliers

Dosing Information

Half-Life

~200-300 hours

Typical Dose

0.25–1 mg

Frequency

Once daily (oral)

Cycle Length

12-24 weeks under medical supervision

Administration Routes:
oral

Benefits

  • Potent appetite suppression
  • Increased resting metabolic rate and thermogenesis
  • Potential cognitive enhancement effects
  • Significant weight loss observed in clinical trials (up to 12%)

Side Effects

Increased heart rate and blood pressuremild
Dry mouth and insomniamild
Constipationmild
Mood changes and anxietymild
Potential for dependencemild

Mechanism of Action

1

Inhibits reuptake of norepinephrine, dopamine, and serotonin

2

Enhances sympathetic nervous system activity to boost thermogenesis

3

Modulates hypothalamic appetite regulation via monoamine signaling

Contraindications

Do not use this peptide if any of the following apply:

  • Uncontrolled hypertension or cardiovascular disease
  • History of stroke or heart attack
  • Concurrent use of MAO inhibitors or other stimulants
  • Anxiety disorders or insomnia
  • Pregnancy or breastfeeding

Storage & Reconstitution

Unreconstituted (Powder)

Temperature15–25°C (59–77°F)
DurationUp to 3 months

Reconstituted (Mixed)

Temperature15–25°C (59–77°F)
Duration2-4 weeks

For suppliers & labs

Building a Tesofensine catalogue? Custom waterproof vial & pen labels (zero MOQ, UK print) on PepPrint →

Research Summary

Preclinical

Phase 2 trials demonstrated that tesofensine 0.5 mg produced approximately 12.8% body weight loss over 24 weeks, roughly double that of existing anti-obesity medications at the time. Phase 3 trials (TESORA) are ongoing in several countries. The compound also showed improvements in metabolic parameters including HbA1c and lipid profiles. Cardiovascular safety monitoring remains a key focus.

Frequently Asked Questions

Common questions about Tesofensine

UK-Specific Information

Exclusive data points and guidance for UK residents using Tesofensine

UK Lab Testing

UK Lab Testing

Recommended labs: Medichecks, Thriva (£89-£149 for peptide safety panel)

Why this matters: UK-specific lab testing guidance not available on US competitor sites

Commonly Stacked With

Share on TikTok

Generate a trackable link to share this peptide information on TikTok